Different chemotherapy regimens had different pCR rates, ranging from 2% to 17%.[18] A study of paclitaxel combined with cisplatin/nedaplatin in NCT was confirmed, the pCR rate of the scheme could reach 20.5%, and the survival time of the patients was prolonged, P = .049.[19] In our study, all patients receiving the albumin-binding paclitaxel combined with nedaplatin regimen achieved R0 resection, and 17.1% of the patients arrived at pCR, suggesting that many ESCC patients might benefit from this regimen. This evidence concerns the gene ALB and esophageal squamous cell carcinoma.